The COVID-19 pandemic did not merely put hospitals, laboratories, and public health agencies under extraordinary pressure. It also turned state capitols into unexpected battlegrounds over who should decide what counts as appropriate medical care. Physicians traditionally make treatment decisions using clinical evidence, professional standards, patient circumstances, and informed consent. During the pandemic, however, some state legislators proposed laws designed to protect clinicians who prescribed controversial COVID-19 treatments such as ivermectin and hydroxychloroquine from professional discipline.

Supporters frequently described these measures as protections for medical freedom, physician autonomy, and patients’ right to try available medicines. Critics saw something very different: political intervention that could weaken the medical standard of care and give misinformation a legislative life jacket.

The distinction matters. Off-label prescribing is neither unusual nor automatically inappropriate. Physicians in the United States generally may prescribe an FDA-approved medicine for an unapproved use when their medical judgment and credible scientific evidence support doing so. The problem arises when lawmakers attempt to guarantee special protection for a particular treatment regardless of whether increasingly strong evidence shows that treatment does not work.

What Does the Medical Standard of Care Actually Mean?

The phrase standard of care sounds like a mysterious rule kept in a locked cabinet somewhere between the hospital pharmacy and the lawyers’ office. In reality, it is a fundamental principle of medicine and medical liability.

Generally speaking, clinicians are expected to provide the level of care that a reasonably competent professional would provide under comparable circumstances. Exact legal definitions vary by state, specialty, and factual situation. Medical boards also operate under state-specific statutes defining unprofessional conduct, inappropriate prescribing, negligence, record-keeping requirements, and other duties.

The standard of care does not mean physicians must behave like robots reading identical scripts. Medicine requires judgment. Doctors routinely choose among reasonable alternatives, modify treatments for unusual patients, prescribe drugs off-label, and change practice as new evidence emerges.

That flexibility is precisely why professional oversight matters. Clinical freedom is supposed to coexist with professional responsibility.

Off-label treatment is not the same as experimental guesswork

An FDA-approved medication may legally be used for a condition that does not appear on its approved label. Cancer medicine, pediatrics, psychiatry, and other specialties have long relied on carefully considered off-label prescribing.

The FDA itself acknowledges that healthcare professionals generally can prescribe approved drugs for unapproved uses based on medical judgment. But the agency also emphasizes an important point: FDA approval of the original drug does not establish that every possible off-label use is safe or effective.

In other words, “the drug is FDA approved” is not a magical sentence that converts every proposed use into evidence-based medicine.

How Ivermectin and Hydroxychloroquine Became Political Symbols

Early in the pandemic, researchers understandably examined existing medications that might be repurposed against SARS-CoV-2. That was sensible. When a new disease appears and proven therapies are scarce, scientists investigate plausible options quickly.

Hydroxychloroquine became one of the first high-profile candidates. The FDA issued an Emergency Use Authorization in March 2020 for limited use of chloroquine and hydroxychloroquine, but revoked it on June 15, 2020, after accumulating evidence indicated that the drugs were unlikely to provide the anticipated benefit for COVID-19 and that their risks could outweigh those benefits.

Ivermectin followed a similar journey from scientific hypothesis to cultural phenomenon. It is a useful antiparasitic drug for approved indications, but that fact says nothing about whether it treats a viral respiratory infection.

Large randomized studies ultimately failed to demonstrate a meaningful clinical benefit for ivermectin in treating ordinary COVID-19. The TOGETHER trial published in The New England Journal of Medicine found that ivermectin did not significantly reduce hospitalization or prolonged emergency observation. The U.S. ACTIV-6 randomized trial, published in JAMA, found no significant improvement in sustained recovery among outpatients. A later ACTIV-6 trial using a higher dose for a longer duration also failed to show meaningful benefit.

Evidence changed, but politics sometimes did not

This is where science and politics operate differently. Scientific recommendations are supposed to change when better evidence arrives. A hypothesis can be exciting on Monday, disappointing by Friday, and discarded after a sufficiently convincing randomized trial.

Political identities are stickier.

Once ivermectin and hydroxychloroquine became symbols in broader disputes over pandemic mandates, government authority, pharmaceutical companies, and public health institutions, debates about them were no longer merely debates about pharmacology. For some activists and politicians, skepticism toward the medical establishment itself became part of the argument.

The medicine cabinet had acquired a campaign bumper sticker.

State Legislatures Enter the Treatment Room

During 2021 and 2022, lawmakers in numerous states introduced measures limiting the ability of medical boards, hospitals, pharmacists, or other professional bodies to take action against clinicians using controversial COVID-19 treatments.

North Dakota enacted legislation protecting certain healthcare professionals from discipline merely for prescribing, dispensing, or administering ivermectin, while preserving regulatory authority in circumstances involving issues such as substandard care or patient harm.

Other proposals went further. Bills considered in states including Colorado, Pennsylvania, Wisconsin, Indiana, New Hampshire, Virginia, Florida, and elsewhere attempted in various ways to protect off-label COVID-19 prescribing, change disciplinary thresholds, restrict pharmacists’ ability to refuse prescriptions, or make it harder to sanction clinicians for COVID-related statements.

Not all of those proposals became law. Some died in committee, were rejected, or were modified. That distinction is important: the legislative history shows a broad political movement, not a single nationwide rule.

A 2022 review reported that lawmakers in roughly half the states had considered measures affecting the regulation of clinicians promoting disputed COVID treatments or information. The Federation of State Medical Boards simultaneously warned that medical boards needed to retain adequate authority to protect patients.

Why Supporters Called the Bills “Medical Freedom”

It would be too easyand inaccurateto pretend supporters had no arguments at all. Their concerns generally fell into several categories.

Concern about excessive regulatory control

Some lawmakers and physicians worried medical boards could punish doctors simply because they disagreed with prevailing public health recommendations. Because scientific understanding evolves, they argued, a government-backed consensus should not become an unquestionable doctrine.

Support for physician autonomy

Supporters also argued that physicians treating individual patients should have greater freedom than government agencies writing population-level recommendations.

That principle has legitimate roots. Medical organizations themselves recognize the importance of professional judgment and evidence-based off-label prescribing.

Patient choice

Another argument centered on informed consent. If a patient understands the potential risks and uncertainties and still wants a treatment, proponents asked, why should government stop a licensed physician from prescribing it?

These questions deserve serious consideration. Medicine should not become intellectually frozen, and regulators should not punish legitimate scientific disagreement merely because a minority view is unpopular.

But that does not automatically justify legislation shielding a favored intervention from ordinary professional scrutiny.

The Critical Difference Between Medical Freedom and Medical Immunity

A physician’s freedom to consider an unconventional treatment is different from a statutory promise that regulators cannot investigate that treatment under normal standards.

Imagine a law saying an engineer may experiment with innovative bridge designs. Reasonable enough. Now imagine the law says the engineering board cannot investigate the engineer merely because a bridge design ignored established safety calculations. Suddenly “innovation” is doing quite a bit of heavy lifting.

Medical innovation works best when uncertainty is acknowledged, evidence is collected, risks are explained, records are maintained, outcomes are evaluated, and physicians remain accountable for unreasonable decisions.

Giving one politically popular drug a special regulatory shield reverses the usual process. Instead of evidence shaping policy, policy risks determining which evidence professionals are allowed to act upon.

Medical Misinformation Makes the Problem Harder

The Federation of State Medical Boards warned during the pandemic that physicians spreading false COVID-19 information could face professional consequences. Its later ethics guidance emphasized that physicians hold a position of exceptional public trust and have responsibilities when communicating medical information.

The American Medical Association likewise adopted policies urging stronger responses to health disinformation disseminated by healthcare professionals.

There is, however, a legitimate free-speech complication. A physician discussing politics as a private citizen is not necessarily acting as someone’s treating doctor. Scholars have debated how far medical boards should go when regulating public statements, particularly when statements occur outside a physician-patient relationship.

That debate should not be trivialized. Constitutional protections matter.

A 2024 analysis of disciplinary proceedings in California, Florida, New York, Pennsylvania, and Texas found that community-directed medical misinformation accounted for only a tiny share of medical-board discipline. Commentators responding to the study argued that sanctions for public speech should remain uncommon and focus on particularly egregious professional conduct with meaningful potential for harm.

Why Informed Consent Alone Cannot Solve the Problem

Many legislative proposals emphasized informed consent. But signing a consent form does not eliminate every professional obligation.

Meaningful informed consent depends on accurate information. A patient cannot intelligently evaluate a treatment if benefits are exaggerated, contrary evidence is ignored, or proven alternatives are misrepresented.

Suppose a clinician tells a patient, “This treatment is controversial, high-quality studies have not demonstrated meaningful benefit, and established alternatives may be more appropriate.” That is one kind of discussion.

Now suppose another clinician says, “This treatment definitely works, but regulators and pharmaceutical companies are hiding the truth.” A patient’s signature underneath that explanation does not magically transform misinformation into informed consent.

Consent works only when the information preceding the consent deserves the adjective informed.

The Cost of Chasing Unproven COVID Treatments

The most obvious risk from an ineffective treatment is adverse effects. But the larger danger may be opportunity cost.

A patient relying on an ineffective therapy may delay seeking medical attention or miss the short window during which an evidence-supported antiviral can be most useful.

Current CDC clinical guidance advises clinicians to consider early antiviral treatment for eligible patients at increased risk of severe COVID-19. Options include nirmatrelvir with ritonavir and remdesivir, with treatment generally needing to begin soon after symptoms start.

The Infectious Diseases Society of America continues to recommend against ivermectin for COVID-19 treatment and against hydroxychloroquine for hospitalized COVID-19 patients.

Public Trust Is Part of the Standard of Care Conversation

The pandemic demonstrated that misinformation is not merely a collection of incorrect Facebook posts. It can alter behavior.

When medical credentials accompany unsupported claims, the claims gain authority. A statement from “someone on the internet” may be ignored. The same statement from a person introduced as a physician can sound dramatically more credible.

This creates a difficult responsibility for licensing bodies. Regulators should not become political speech police, but neither can professional credentials become a universal disclaimer that says, “Anything goes.”

The long-term challenge is finding a line that protects scientific disagreement while still permitting intervention against demonstrably dangerous professional misconduct.

What Better State Policy Could Look Like

Protect evidence-based clinical judgment

Legislatures can explicitly recognize physicians’ ability to prescribe off-label without granting special immunity to particular politically popular drugs. The question should remain whether the decision was medically reasonable under the circumstances.

Preserve normal medical-board authority

Boards should be able to examine allegations involving negligence, inadequate informed consent, inappropriate prescribing, poor documentation, conflicts of interest, and patient harm using established procedures.

Distinguish disagreement from demonstrable falsehoods

Changing evidence should be handled differently from repeatedly asserting claims that have been convincingly contradicted by high-quality evidence. Medicine progresses because hypotheses can be challenged, tested, and abandoned.

Keep lawmakers focused on rules, not prescriptions

State legislatures have an important role in defining the legal structure of medicine. They are less well suited to deciding that Drug A deserves preferential protection while Drug B does not. Clinical evidence can change far faster than statutes.

Experience-Based Lessons From the COVID Treatment Controversy

The most useful experience to carry forward from the COVID treatment fight is not that unconventional ideas should automatically be rejected. Quite the opposite: early investigation of unconventional ideas is essential during a health emergency. The real lesson is that uncertainty must be managed honestly.

At the beginning of the pandemic, clinicians were working with incomplete information. Hospitals changed protocols rapidly. Researchers tested repurposed medications because there were few proven treatments. Patients understandably wanted anything that might help. Under those conditions, experimentation accompanied by careful monitoring was not evidence of failure; it was part of medicine responding to a new disease.

The trouble came when preliminary hypotheses hardened into identities.

Healthcare workers repeatedly encountered patients arriving with firm opinions about treatments they had learned about from television programs, podcasts, politicians, social media groups, or online physicians. Some patients wanted ivermectin. Others asked for hydroxychloroquine. Still others believed hospitals deliberately withheld those medications for financial or political reasons.

Those interactions illustrate how medical misinformation changes clinical practice even when nobody takes a dangerous dose of anything. A physician may have to spend valuable appointment time rebuilding trust before discussing oxygen levels, drug interactions, risk factors, or treatments supported by stronger evidence.

Another practical lesson concerns the difference between early evidence and mature evidence. A small observational study may justify further research. It rarely justifies certainty. When larger randomized trials become available, responsible clinical practice should update accordingly.

The pandemic also demonstrated why personal experience must be treated cautiously. A physician may sincerely say, “I gave this drug to hundreds of patients, and most recovered.” But most people with mild COVID-19 recover anyway. Without an appropriate comparison group, it is extremely difficult to know whether a treatment caused the observed outcome.

This is exactly why randomized controlled trials exist. Human beings are wonderful at observing patterns and notoriously enthusiastic about assigning causes to them.

Legislators faced the same psychological trap. Compelling testimony from a doctor or recovered patient can feel more persuasive than a statistical confidence interval. Personal stories have faces, voices, and emotion. Clinical trial tables have columns. Democracy understandably prefers the microphone, but medicine sometimes needs the spreadsheet.

Another experience worth remembering is that aggressive censorship is not necessarily the solution. Attempts to suppress discussion can strengthen conspiracy theories by making advocates believe authorities are afraid of debate. A healthier approach combines transparency with evidence: explain what was tested, what researchers found, what remains uncertain, and what evidence would change current recommendations.

Finally, the controversy showed why institutional trust is precious and surprisingly easy to spend. Government agencies, medical boards, hospitals, and physicians should acknowledge errors and uncertainty when they occur. Recommendations during a new pandemic will inevitably change. Explaining why they changed is far more credible than pretending experts were never uncertain.

Good science does not promise permanent certainty. It promises a process for becoming less wrong.

Conclusion

The debate over state protection for disputed COVID-19 treatments is ultimately larger than ivermectin or hydroxychloroquine. It asks who should determine the boundaries of competent medical practice when politics, professional autonomy, patient choice, scientific uncertainty, and public safety collide.

Physicians need room to exercise judgment. Patients deserve meaningful choices. Legislatures have legitimate authority to structure healthcare regulation. But none of those principles requires lawmakers to place favored treatments beyond normal evidence-based scrutiny.

The strongest safeguard for both medical freedom and patient safety is not political immunity. It is a system in which doctors can explore reasonable alternatives while remaining accountable to credible evidence, honest informed consent, professional standards, and changing scientific knowledge.

That system can occasionally be frustrating. Science has committees, peer review, revisions, negative trials, and enough statistical terminology to make a dictionary request early retirement. Yet those inconveniences exist for a reason: patients deserve treatments chosen because evidence supports them, not because a drug won a popularity contest at the statehouse.

Note: This article synthesizes information and research from U.S. regulatory agencies, professional medical organizations, academic journals, medical ethics literature, state legislative materials, and major reporting, including the FDA, CDC, Infectious Diseases Society of America, Federation of State Medical Boards, American Medical Association, JAMA, The New England Journal of Medicine, Cornell Legal Information Institute, CIDRAP, and state legislative records. It is intended for general educational and informational purposes and is not individual medical or legal advice.